MACROGENICS INC
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:
| MacroGenics, Inc. | |
| By: | /s/ Scott Koenig |
| Scott Koenig, M.D., Ph.D. | |
| President and CEO and Director |
Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Scott Koenig | President and CEO and Director(Principal Executive Officer) | March 20, 2025 |
| Scott Koenig, M.D., Ph.D. | ||
| /s/ James Karrels | Senior Vice President, Chief Financial Officer and Secretary (Principal Financial Officer) | March 20, 2025 |
| James Karrels | ||
| /s/ Beth Smith | Vice President, Controller and Treasurer(Principal Accounting Officer) | March 20, 2025 |
| Beth Smith | ||
| /s/ Karen Ferrante, M.D. | Director | March 20, 2025 |
| Karen Ferrante, M.D. | ||
| /s/ William Heiden | Director | March 20, 2025 |
| William Heiden | ||
| /s/ Edward Hurwitz | Director | March 20, 2025 |
| Edward Hurwitz | ||
| /s/ Scott Jackson | Director | March 20, 2025 |
| Scott Jackson | ||
| /s/ Meenu Chhabra Karson | Director | March 20, 2025 |
| Meenu Chhabra Karson | ||
| /s/ Margaret A. Liu, M.D. | Director | March 20, 2025 |
| Margaret A. Liu, M.D. | ||
| /s/ Federica O’Brien | Director | March 20, 2025 |
| Federica O’Brien | ||
| /s/ Jay Siegel, M.D. | Director | March 20, 2025 |
| Jay Siegel, M.D. | ||
| /s/ David Stump, M.D. | Director | March 20, 2025 |
| David Stump, M.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| PageNumber | |
| Report of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42) | F - 1 |
|---|---|
| Consolidated Balance Sheets at December 31, 2024 and December 31, 2023 | F - 3 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022 | F - 4 |
| Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024, 2023 and 2022 | F - 5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 | F - 6 |
| Notes to Consolidated Financial Statements | F - 7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.